Antibiotic Regimen for MRSA, Anaerobes, and Gram-Negatives
For empiric coverage of MRSA, anaerobes, and gram-negative organisms, use vancomycin or linezolid PLUS piperacillin-tazobactam, or alternatively vancomycin/linezolid PLUS a carbapenem (imipenem, meropenem, or ertapenem). 1
Recommended Regimens
First-Line Combination Options
The IDSA guidelines for polymicrobial infections explicitly recommend broad empiric coverage with the following combinations 1:
Option 1: Anti-MRSA agent + Beta-lactam/Beta-lactamase inhibitor
- Vancomycin 15 mg/kg IV every 12 hours PLUS
- Piperacillin-tazobactam 3.375 g IV every 6 hours or 4.5 g IV every 8 hours
Option 2: Anti-MRSA agent + Carbapenem
- Vancomycin 15 mg/kg IV every 12 hours PLUS
- Meropenem 1 g IV every 8 hours, OR
- Imipenem-cilastatin 500 mg IV every 6 hours, OR
- Ertapenem 1 g IV every 24 hours
Option 3: Anti-MRSA agent + Third-generation cephalosporin + Anaerobic coverage
- Vancomycin 15 mg/kg IV every 12 hours PLUS
- Ceftriaxone 1 g IV every 24 hours PLUS
- Metronidazole 500 mg IV every 8 hours
Alternative Anti-MRSA Agents
While vancomycin is standard, linezolid may be substituted for vancomycin and has demonstrated superior clinical success rates in recent meta-analyses 2, 3. Linezolid 600 mg IV/PO every 12 hours showed improved clinical cure rates (RR 1.71) compared to vancomycin across multiple infection types 2. However, monitor for thrombocytopenia with linezolid use 3.
Daptomycin is another alternative for MRSA coverage, particularly in bloodstream infections where it ranked highest in effectiveness (73.0% SUCRA) 3. Use daptomycin 6-10 mg/kg IV every 24 hours, but do NOT use daptomycin for pneumonia as it is inactivated by pulmonary surfactant 4.
Single-Agent Options
If a single-agent regimen is preferred for convenience, the following carbapenems provide coverage against gram-negatives and anaerobes but require addition of an anti-MRSA agent 1:
- Piperacillin-tazobactam 3.375 g IV every 6 hours (covers gram-negatives and anaerobes, NOT MRSA)
- Meropenem 1 g IV every 8 hours (covers gram-negatives and anaerobes, NOT MRSA)
- Imipenem-cilastatin 500 mg IV every 6 hours (covers gram-negatives and anaerobes, NOT MRSA)
None of these single agents cover MRSA, so vancomycin, linezolid, or daptomycin must be added.
Clinical Context Matters
The guideline emphasizes that polymicrobial infections (requiring this triple coverage) typically occur in four settings 1:
- Perianal abscesses, penetrating abdominal trauma, or bowel surgery
- Decubitus ulcers
- Injection drug use sites
- Spread from genital sites (Bartholin abscess, episiotomy wounds)
Important Caveats
Ceftobiprole limitation: While ceftobiprole covers MRSA and gram-negatives, it has poor activity against Bacteroides and other anaerobic gram-negatives, making it inadequate as monotherapy for this indication 5.
Vancomycin considerations: Despite being first-line, vancomycin showed inferior microbiological success rates compared to telavancin (RR 0.74) and lower clinical success rates than linezolid in skin/soft tissue infections and pneumonia 2.
Adjust based on culture results: Once susceptibilities return, narrow therapy appropriately. For confirmed MSSA, switch to cefazolin or antistaphylococcal penicillins 4.